DXR | Daxor Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	9.16 - 9.50
52 Week Range	7.11 - 10.04
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	4,635
Average Volume	3,732
Shares Outstanding	4,836,930
Market Cap	45,950,835
Sector	Healthcare
Industry	Medical - Instruments & Supplies
IPO Date	1983-07-25

Valuation
Profitability
Growth
Health
P/E Ratio	8.19
Forward P/E Ratio	N/A
EPS	1.16
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	37
Country	USA
Website	DXR

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

DXR's peers: INFU, MHUA, KRMD, LMAT, POCI, UTMD, MLSS, PDEX, NXGL, NYXH, POAI, SMTI

*Chart delayed

Analyzing fundamentals for DXR we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is good and Health is very weak. For more detailed analysis please see DXR Fundamentals page.

Watching at DXR technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on DXR Technicals page.